It is also possible that IL-6 may act on other sites not blocked by α-IL-6R mAb, and that this may yield a potential advantage of using α-IL-6 mAb to treat CRS brought about by a viral infection. The gene discussed is IL6; the disease is congenital rubella syndrome.